Brainstorm Cell Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Brainstorm Cell Therapeutics Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.1 million, a decrease from the $2.9 million loss recorded in the same period of the previous year. The company’s operating expenses totaled approximately $2.0 million, down from $3.1 million in the first quarter of 2025. This reduction was primarily driven by lower research and development costs, which fell to $762,000 from $1.3 million, and a decrease in general and administrative expenses, which declined to $1.3 million from $1.8 million. The basic and diluted net loss per share improved to $0.19 from $0.45 year-over-year, reflecting a higher weighted average number of shares outstanding, which increased to 11,034,775 from 6,342,002.

In terms of liquidity, Brainstorm reported cash, cash equivalents, and restricted cash of $206,000 as of March 31, 2026, a significant decrease from $1.8 million at the end of 2025. The company has been actively seeking additional funding to support its operations and clinical development efforts. In May 2026, Brainstorm raised $200,000 through private placements, issuing shares and warrants to accredited investors. The company is exploring various financing options, including public and private sales of common stock and convertible promissory notes, to meet its capital needs.

Strategically, Brainstorm continues to focus on its proprietary NurOwn® technology, which is aimed at treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company has faced challenges with its Biologics License Application (BLA) for NurOwn®, which was withdrawn in November 2023 after the FDA advisory committee voted against its effectiveness for mild to moderate ALS. Following this, Brainstorm has engaged in discussions with the FDA to outline a path forward, including plans for a Phase 3b registrational trial, which has received a Special Protocol Assessment agreement from the FDA.

Operationally, Brainstorm has maintained a workforce of 19 employees, primarily based in the United States and Israel. The company’s research and development activities are concentrated in Israel, where it has established partnerships for the manufacturing of NurOwn®. Despite the setbacks in regulatory approvals, Brainstorm remains committed to advancing its clinical programs and is actively working on enhancing its manufacturing capabilities to support future trials and potential commercialization of its therapies. The company’s outlook remains cautious, with management acknowledging the need for substantial additional financing to continue its operations and clinical development efforts.